Biotech

All Articles

AstraZeneca spends CSPC $100M for preclinical cardiovascular disease drug

.AstraZeneca has paid CSPC Drug Team $100 million for a preclinical cardiovascular disease drug. The...

Zephyrm seeks Hong Kong IPO to finance period 3 cell therapy tests

.Zephyrm Bioscience is gusting toward the Hong Kong stock market, submitting (PDF) for an IPO to ban...

Frazier Life Sciences collects $630M for tiny, mid-cap biotechs

.Frazier Life Sciences has sourced a further $630 thousand for its fund concentrated on tiny and als...

GigaGen gets up to $135M BARDA money to hammer botulism

.Antibody connoisseur GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its...

GPCR organization Septerna files for IPO on toughness of preclinical data

.Septerna will learn just how a biotech without "any kind of purposeful clinical records" meals in t...

Kurma closes initially $154M haul for largest biotech fund as yet

.European VC agency Kurma Allies has revealed its own most current biotech fund, along with 140 mill...

Prothena advertises one officer while one more places-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of considerable leadership hirings, shooting...

Editas cashes in on Tip Cas9 licensing civil liberties for $57M

.Versus the background of a Cas9 patent battle that declines to pass away, Editas Medicine is cashin...

Ultragenyx modifies genetics treatment dosing to dial up efficacy

.A minority of patients taking Ultragenyx Drug's Wilson health condition gene therapy UX701 have com...

Biopharma unemployment price supports in Q3: Brutal Biotech analysis

.As summertime warmth looks to cool winds, wishes that this year will bring extensive industry relie...